TransMedics Group (NASDAQ: TMDX) insider transactions
In the twelve months to 10 November 2026, executives and directors of TransMedics Group reported 11 open-market sales of 34,749 shares ($4.3m) and 2 open-market purchases of 10,111 shares ($1.1m), by 7 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 28 October 2026 | Araujo Fernando N. | See Remarks | Grant or award | +22,969 | — | 22,969 | Form 4 |
| 11 September 2026 | Weill David | Director | Open-market purchase | +1,336 | $81.63 | 16,392 | Form 4 |
| 17 August 2026 | Tobin James R | Director | Gift | −18,000 | — | 0 | Form 4 |
| 10 July 2026 | Hassanein Waleed H | President & CEO | Grant or award | +49,669 | — | 171,093 | Form 4 |
| 10 July 2026 | Hernandez Gerardo | Chief Financial Officer | Grant or award | +17,246 | — | 31,935 | Form 4 |
| 10 July 2026 | Corcoran Nicholas | See remarks | Grant or award | +11,727 | — | 41,558 | Form 4 |
| 15 June 2026 | Gunderson Thomas J. | Director | Option exercise | +19,285 | $2.21 | 26,266 | Form 4 |
| 15 June 2026 | Gunderson Thomas J. | Director | Open-market sale | −9,624 | $75.06 | 16,642 | Form 4 |
| 20 May 2026 | Kania Edwin | Director | Grant or award | +2,922 | — | 263,732 | Form 4 |
| 20 May 2026 | Tobin James R | Director | Grant or award | +2,922 | — | 6,981 | Form 4 |
| 20 May 2026 | Basile Edward M | Director | Grant or award | +2,922 | — | 5,788 | Form 4 |
| 20 May 2026 | Gunderson Thomas J. | Director | Grant or award | +2,922 | — | 6,981 | Form 4 |
| 20 May 2026 | Raines Merilee | Director | Grant or award | +2,922 | — | 6,981 | Form 4 |
| 20 May 2026 | Weill David | Director | Grant or award | +2,922 | — | 15,056 | Form 4 |
| 20 May 2026 | Lovell Stephanie | Director | Grant or award | +2,922 | — | 5,788 | Form 4 |
| 19 May 2026 | Forsyth Matthew S. | See Remarks | Grant or award | +15,409 | — | 15,409 | Form 4 |
| 4 March 2026 | Weill David | Director | Option exercise | +3,571 | $14.20 | 15,705 | Form 4 |
| 4 March 2026 | Weill David | Director | Open-market sale | −3,571 | $146.82 | 12,134 | Form 4 |
| 4 March 2026 | Lovell Stephanie | Director | Open-market sale | −1,193 | $149.62 | 2,866 | Form 4 |
| 4 March 2026 | Hernandez Gerardo | Chief Financial Officer | Option exercise | +1,324 | $77.12 | 16,013 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the TransMedics Group page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.